Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model

References

• Ehteshami-Afshar S, FitzGerald JM, Doyle-Waters MM, Sadatsafavi M. The global economic burden of asthma and chronic obstructive pulmonary disease. Int J Tuberc Lung Dis. 2016;20(1):11–23. doi:10.5588/ijtld.15.0472
   PubMed Web of Science ®Google Scholar
• Iheanacho I, Zhang S, King D, Rizzo M, Ismaila AS. Economic burden of Chronic Obstructive Pulmonary Disease (COPD): a systematic literature review. Int J Chron Obstruct Pulmon Dis. 2020;15:439–460. doi:10.2147/COPD.S234942
   PubMed Web of Science ®Google Scholar
• GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204–1222.
   PubMed Web of Science ®Google Scholar
• Foo J, Landis SH, Maskell J, et al. Continuing to confront COPD international patient survey: economic impact of COPD in 12 countries. PLoS One. 2016;11(4):e0152618. doi:10.1371/journal.pone.0152618
   PubMed Web of Science ®Google Scholar
• British Lung Foundation. Estimating the economic burden of respiratory illness in the UK; 2017. Available from: https://cdn.shopify.com/s/files/1/0221/4446/files/PC-1601_-_Economic_burden_report_FINAL_8cdaba2a-589a-4a49-bd14-f45d66167795.pdf?1309501094450848169. Accessed January, 2021.
   Google Scholar
• Nici L, Mammen MJ, Charbek E, et al. Pharmacologic management of chronic obstructive pulmonary disease. An official American thoracic society clinical practice guideline. Am J Respir Crit Care Med. 2020;201(9):e56–e69. doi:10.1164/rccm.202003-0625ST
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Chronic obstructive pulmonary disease in over 16s: diagnosis and management; 2018. Available from: https://www.nice.org.uk/guidance/ng115/resources/chronic-obstructive-pulmonary-disease-in-over-16s-diagnosis-and-management-pdf-66141600098245. Accessed January, 2021.
   Google Scholar
• Oba Y, Sarva ST, Dias S. Efficacy and safety of long-acting beta-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis. Thorax. 2016;71(1):15–25. doi:10.1136/thoraxjnl-2014-206732
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Price D, Anzueto A, et al. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017;12:907–922. doi:10.2147/COPD.S130482
   PubMed Web of Science ®Google Scholar
• Maltais F, Bjermer L, Kerwin EM, et al. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respir Res. 2019;20(1):238. doi:10.1186/s12931-019-1193-9
   PubMed Web of Science ®Google Scholar
• Briggs AH, Baker T, Risebrough NA, et al. Development of the galaxy Chronic Obstructive Pulmonary Disease (COPD) model using data from ECLIPSE: internal validation of a linked-equations cohort model. Med Decis Making. 2017;37(4):469–480. doi:10.1177/0272989X16653118
   PubMed Web of Science ®Google Scholar
• Hoogendoorn M, Feenstra TL, Asukai Y, et al. External validation of health economic decision models for Chronic Obstructive Pulmonary Disease (COPD): report of the third COPD modeling meeting. Value Health. 2017;20(3):397–403. doi:10.1016/j.jval.2016.10.016
   PubMed Web of Science ®Google Scholar
• Risebrough NA, Briggs A, Baker TM, et al. Validating a model to predict disease progression outcomes in patients with COPD. Value Health. 2014;17(7):A560–561. doi:10.1016/j.jval.2014.08.1852
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Report; 2021. Available from: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf. Accessed January, 2021.
   Google Scholar
• Gedebjerg A, Szépligeti SK, Wackerhausen L-MH, et al. Prediction of mortality in patients with chronic obstructive pulmonary disease with the new Global Initiative for Chronic Obstructive Lung Disease 2017 classification: a cohort study. Lancet Respir Med. 2018;6(3):204–212. doi:10.1016/S2213-2600(18)30002-X
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in Chronic Obstructive Pulmonary Disease. N Engl J Med. 2010;363(12):1128–1138. doi:10.1056/NEJMoa0909883
   PubMed Web of Science ®Google Scholar
• Rothnie KJ, Mullerova H, Smeeth L, Quint JK. Natural history of chronic obstructive pulmonary disease exacerbations in a general practice-based population with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(4):464–471. doi:10.1164/rccm.201710-2029OC
   PubMed Web of Science ®Google Scholar
• Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J. 2008;31(4):869–873. doi:10.1183/09031936.00111707
   PubMed Web of Science ®Google Scholar
• Agusti A, Calverley PM, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11(1):122. doi:10.1186/1465-9921-11-122
   PubMed Web of Science ®Google Scholar
• Exuzides A, Colby C, Briggs AH, et al. Statistical modeling of disease progression for chronic obstructive pulmonary disease using data from the ECLIPSE study. Med Decis Making. 2017;37(4):453–468. doi:10.1177/0272989X15610781
   PubMed Web of Science ®Google Scholar
• Ismaila AS, Risebrough N, Schroeder M, et al. Cost-effectiveness of once-daily single-inhaler triple therapy in COPD: the IMPACT trial. Int J Chron Obstruct Pulmon Dis. 2019;14:2681–2695. doi:10.2147/COPD.S216072
   PubMed Web of Science ®Google Scholar
• Jones PW, Adamek L, Nadeau G, Banik N. Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification. Eur Respir J. 2013;42(3):647–654. doi:10.1183/09031936.00125612
   PubMed Web of Science ®Google Scholar
• Starkie HJ, Briggs AH, Chambers MG, Jones P. Predicting EQ-5D values using the SGRQ. Value Health. 2011;14(2):354–360. doi:10.1016/j.jval.2010.09.011
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal; 2013. Available from: https://www.nice.org.uk/process/pmg9/chapter/foreword. Accessed March, 2021.
   Google Scholar
• National Institute for Health and Care Excellence (NICE). Chronic obstructive disease in over 16s: diagnosis and management [H] Economic model report; 2018. Available from: https://www.nice.org.uk/guidance/ng115/evidence/h-economic-model-report-pdf-6602768757. Accessed October, 2020.
   Google Scholar
• Han MK, Quibrera PM, Carretta EE, et al. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017;5(8):619–626. doi:10.1016/S2213-2600(17)30207-2
   PubMed Web of Science ®Google Scholar
• Agusti A, Edwards LD, Celli B, et al. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J. 2013;42(3):636–646. doi:10.1183/09031936.00195212
   PubMed Web of Science ®Google Scholar
• Mackay AJ, Kostikas K, Roche N, et al. Impact of baseline symptoms and health status on COPD exacerbations in the FLAME study. Respir Res. 2020;21(1):93. doi:10.1186/s12931-020-01354-8
   PubMed Web of Science ®Google Scholar
• Kostikas K, Greulich T, Mackay AJ, et al. Treatment response in COPD: does FEV1 say it all? A post hoc analysis of the CRYSTAL study. ERJ Open Res. 2019;5(1):00243–02018. doi:10.1183/23120541.00243-2018
   PubMedGoogle Scholar
• Casanova C, de Torres JP, Aguirre-Jaíme A, et al. The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort. Am J Respir Crit Care Med. 2011;184:1015–1021. doi:10.1164/rccm.201105-0831OC
   PubMed Web of Science ®Google Scholar
• Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T, Mishima M. Longitudinal deteriorations in patient reported outcomes in patients with COPD. Respir Med. 2007;101(1):146–153. doi:10.1016/j.rmed.2006.04.001
   PubMed Web of Science ®Google Scholar
• Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5(4):549–555. doi:10.1513/pats.200709-148ET
   PubMedGoogle Scholar
• Chen W, FitzGerald JM, Sin DD, Sadatsafavi M; Canadian Respiratory Research Network. Excess economic burden of comorbidities in COPD: a 15-year population-based study. Eur Respir J. 2017;50(1):1700393. doi:10.1183/13993003.00393-2017
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). British National Formulary; 2020. Available from: https://bnf.nice.org.uk/. Accessed January, 2021.
   Google Scholar
• Office for National Statistics (ONS). EARN01: average weekly earnings; 2020. Available from: https://www.ons.gov.uk/employmentandlabourmarket/peopleinwork/earningsandworkinghours/datasets/averageweeklyearningsearn01/current. Accessed August, 2020.
   Google Scholar
• Meguro M, Barley EA, Spencer S, Jones PW. Development and validation of an improved, COPD-specific version of the St. George respiratory questionnaire. Chest. 2007;132(2):456–463. doi:10.1378/chest.06-0702
   PubMed Web of Science ®Google Scholar